Oncothyreon Inc $2.09

down 0.00


19/9/2014 04:00 PM  |  NASDAQ : ONTY  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ONTY Trend Analysis - it has underperformed the S&P 500 by 3%

Partner Headlines

  1. Events for the Week of Sept. 8-12

    Benzinga
  2. Oncothyreon Plunges On Drug Fail; Wedbush Slashes Price Target

    Benzinga
  3. Morning Market Losers

    Benzinga
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout ...

    Benzinga
  6. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  7. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga
  8. Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial of ...

    Benzinga
  9. Oncothyreon Says ONT-380 Showed Acceptable Safety Profile

    Benzinga
  10. Five Stocks Making Moves Under $10

    Benzinga
  11. Benzinga's Top Pre-Market Gainers

    Benzinga
  12. US Stock Futures Drop Ahead Of New Home Sales, Durable Goods Data

    Benzinga
  13. Oncothyreon Reports Merck Serono Decision to Continue Development of Tecemotide

    Benzinga
  14. UPDATE: Piper Jaffray Initiates Oncothyreon at Underweight on Pipeline ...

    Benzinga
  15. UPDATE: Wedbush Securities Downgrades Oncothyreon to Neutral, Lowers PT

    Benzinga
  16. Stocks Hitting 52-Week Lows

    Benzinga
  17. Morning Market Losers

    Benzinga
  18. A Peek Into The Market Before The Trading Starts

    Benzinga
  19. Oncothyreon's L-BLP25 Did Not Meet Primary Endpoint in Lung Cancer Trial

    Benzinga
  20. Benzinga's Top Pre-Market Gainers

    Benzinga
  21. UPDATE: Stifel Nicolaus Initiates Oncothyreon at Buy with $10 PT on Stimuvax ...

    Benzinga
  22. Oncothyreon Announces Presentation of PX-866 Clinical Data at American ...

    Benzinga
  23. Stocks Plummet on Global Growth Worries

    MarketIntelligenceCenter
  24. Stocks Slide as Greece Deadline Approaches

    MarketIntelligenceCenter
  25. Oncothyreon Inc. (ONTY) Loses 37% On Wider-Than-Expected Loss

    MarketIntelligenceCenter
  26. Oncothyreon Plunges 40% on Earnings, Date of Final Stimuvax Results

    Benzinga
  27. Cantor Fitzgerald Maintains Buy on Oncothyreon; Phase III Start Trial Continues ...

    Benzinga
  28. Benzinga's Top Pre-Market Losers

    Benzinga
  29. UPDATE: JMP Securities Raises Price Target on Oncothyreon to $14

    Benzinga
  30. HF Manager Shkreli: Betting His Career that Oncothyreon's Stimuvax Drug ...

    Benzinga
  31. Oncothyreon Breeches HOD, Ready to Break Higher

    Benzinga
Trading Center